Selatogrel Administration Following STEMI
Selatogrel is not currently approved or recommended for use in STEMI patients, and the "drug label" information provided refers to Selarid (selamectin), a veterinary parasiticide for dogs and cats, not a human antiplatelet agent.
Critical Clarification
The FDA drug label evidence 1 describes Selarid (selamectin), which is explicitly labeled "Not for human use" and is a topical parasiticide for pets. This is completely unrelated to selatogrel, the investigational P2Y12 receptor antagonist being studied for STEMI.
Current Guideline-Based STEMI Antiplatelet Management
For STEMI patients undergoing primary PCI, current guidelines recommend:
- Aspirin: 162-325 mg loading dose before procedure, followed by 81-325 mg daily maintenance (81 mg preferred) 2
- P2Y12 inhibitor loading doses administered as early as possible or at time of PCI 2:
- Clopidogrel 600 mg, OR
- Prasugrel 60 mg, OR
- Ticagrelor 180 mg
Prehospital P2Y12 inhibitor administration is not routinely recommended for transport times <60 minutes, though may be considered for prolonged transport times >60 minutes 3.
Selatogrel: Investigational Status
Selatogrel is a novel subcutaneous P2Y12 receptor antagonist currently in clinical development but not yet approved for clinical use 4, 5.
Proposed Administration Protocol (Based on Clinical Trials)
From Phase 1 and 2 studies 6, 7:
- Route: Subcutaneous injection via autoinjector for patient self-administration
- Dose: 16 mg single dose at onset of AMI symptoms
- Timing: Intended for prehospital self-administration before first medical contact
- Onset: Achieves >80% platelet inhibition within 15-30 minutes
- Duration: Sustained inhibition for ≥8 hours, reversible within 24 hours
Transition to Oral P2Y12 Therapy
Critical consideration: Switching from selatogrel to oral P2Y12 inhibitors requires careful timing 8:
- If clopidogrel loading dose given 12 hours after selatogrel, a temporary reduction in platelet inhibition occurs between 18-24 hours
- Maintenance therapy with ticagrelor or prasugrel quickly achieves sustained inhibition >80%
- The transition period represents a potential vulnerability window requiring clinical attention
Common Pitfalls
- Most common adverse effect: Transient dyspnea in 7% of patients 7
- Drug interaction: Time-dependent pharmacodynamic interaction with clopidogrel loading doses requires strategic timing 8
- Not yet available: Selatogrel remains investigational and is not approved for routine clinical use
Bottom Line
Selatogrel is not currently part of standard STEMI care. Follow established guidelines using oral P2Y12 inhibitors (ticagrelor 180 mg, prasugrel 60 mg, or clopidogrel 600 mg) administered in the emergency department or catheterization laboratory as early as possible before PCI 2, 3. If selatogrel becomes approved following Phase 3 trials, it would be administered as a 16 mg subcutaneous injection via autoinjector, ideally by the patient at symptom onset before hospital arrival.